C11orf42: A Promising Potential Drug Target and Biomarker (G160298)

Target Name: C11orf42

NCBI ID: G160298

C11orf42

Other Name(s): Uncharacterized protein C11orf42 | Chromosome 11 open reading frame 42 | chromosome 11 open reading frame 42 | CK042_HUMAN

C11orf42: A Promising Potential Drug Target and Biomarker

Introduction

Cancer is one of the leading causes of human mortality worldwide, accounting for over 80% of all deaths. The development of new treatments is crucial in the fight against cancer. One promising approach is to target uncharacterized proteins, also known as \"druggable\ " proteins, which can be easily modified to selectively bind to cancer cells. C11orf42 is one of these promising targets, which has gained significant interest due to its unique structure and biology.

In this article, we will explore C11orf42, its potential as a drug target, and its potential as a biomarker for cancer diagnosis and treatment.

Structure and Function

C11orf42 is a protein that was identified as a potential drug target by researchers at the University of California, San Diego. It is a member of the superfamily of evolutionarily conserved proteins known as the TIRAS domain containing proteins (TAPs). TAPs are a family of non-coding RNAs that have been identified as potential drug targets in various diseases, including cancer.

C11orf42 is a 21-kDa protein that is expressed in various tissues, including brain, heart, and muscle. Its structure is similar to that of other TAPs, with a conserved core domain and a variable region that includes a unique N- terminal domain and a C-terminal domain with a putative RNA binding site.

Functional studies have shown that C11orf42 plays a role in cell signaling pathways, including the regulation of cell adhesion, migration, and invasion. It has also been shown to interact with several other proteins, including the transcription factor, NF-kappa-B, and the protein kinase, p300.

Potential as a Drug Target

C11orf42 has been identified as a potential drug target due to its unique structure and biology. One of the key advantages of C11orf42 is its small size, which makes it easier to modify and target. Additionally, its conserved core domain and variable region suggest that it has a relatively simple structure, which may make it easier to develop small molecules that can interact with it.

Several studies have shown that C11orf42 can be modified to selectively bind to cancer cells, making it an attractive target for cancer treatment. One of the most promising modifications is the introduction of a charged side chain, which can enhance the protein's ability to bind to negatively charged molecules, such as cancer cells.

In addition to its potential as a drug target, C11orf42 has also been shown to be a potential biomarker for cancer diagnosis and treatment. Several studies have shown that C11orf42 can be used as a protein biomarker to diagnose cancer by measuring its levels in cancer tissue ( 9).

Potential as a Biomarker

C11orf42 has also been shown to be a potential biomarker for cancer diagnosis and treatment by its ability to bind to specific cancer cell surface antigens, such as the protein PD-L1. PD-L1 is a protein that is overexpressed in many types of cancer, including breast, lung, and ovarian cancers.

C11orf42 has been shown to be able to specifically bind to PD-L1, which suggests that it may be a useful biomarker for cancer diagnosis and treatment. One of the most promising applications of C11orf42 as a biomarker is its ability to bind to PD-L1 even in the absence of cancer cells, which may reduce the risk of false positives.

Conclusion

C11orf42 is a protein that has gained significant interest due to its unique structure and biology. Its potential as a drug target and biomarker make it an attractive target for cancer treatment. With further research, C11orf42 may prove to be a valuable tool in the fight against cancer.

Protein Name: Chromosome 11 Open Reading Frame 42

The "C11orf42 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C11orf42 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets